|
Quilty, when you get a quote on Igen from Yahoo, you can look at the message thread there, and an article was recently quoted from Bloomberg/AOL which should give you some quick insight. John Zweinner, who contributes to this S.I. thread has good understanding of the science involved and his insightful comments have generally pre-dated those of analysts. I have a legal background, and being not privy to investigative reports, etc., am limited to suggesting that I long ago concluded that Igen has a strong position in her litigation from any and everything that I see. While I believe that the stock is seriously undervalued, a bear would surely argue that the company has still made no profit of substance; that the stock has moved from 5 to 46 in a hard run, and since has backed off no lower than 30-35; that the suit could drag on and on and that while there is talk of a point of care device in the offing, none has yet been offered to the market and neither can it be simply assumed that a receptive market awaits. The danger of such a position lies in the facts that "high" throughput devices have been sold to clinics and laboratories at two to three times the anticipated rate; that very high throughput devices have been sold to Pfizer, Aguron and Amgen prior to production (based upon a device that could be so described which was used by Igen to conduct massive testing on contract, for Aguron - and negotiations are underway for some company to market the point of care unit); and finally, while a suit settlement may be somewhat unlikely at a point in time before the approach of a trial date, it seems far more certain that it will produce a large sum for Igen whenever it happens, and that would offer considerable risk to a bear position. |
